ICU Medical, Inc. (ICUI)

Market Cap	3.31B
Revenue (ttm)	2.38B
Net Income (ttm)	-117.69M
Shares Out	24.61M
EPS (ttm)	-4.83
PE Ratio	n/a
Forward PE	19.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,836
Open	135.64
Previous Close	136.00
Day's Range	134.74 - 136.39
52-Week Range	95.44 - 196.26
Beta	0.88
Analysts	Buy
Price Target	197.50 (+46.66%)
Earnings Date	May 8, 2025

About ICUI

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. It offers infusion therapy products, such as needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Mar 31, 1992
• Employees: 15,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ICUI
• Website: https://www.icumed.com

Financial Performance

In 2024, ICU Medical's revenue was $2.38 billion, an increase of 5.44% compared to the previous year's $2.26 billion. Losses were -$117.69 million, 296.9% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for ICUI stock is "Buy." The 12-month stock price forecast is $197.5, which is an increase of 46.66% from the latest price.

Price Target

$197.5

(46.66% upside)

Analyst Consensus: Buy